Evidence map›Paper›PMID 38384443›Full record

ArticleJournal of the Endocrine Society2024

Clinical and Pathological Predictors of Death for Adrenocortical Carcinoma.

Eduardo Pato, Victor Srougi, Claudia Zerbini, Felipe L Ledesma, Fabio Tanno, Madson Q Almeida, William Nahas, Ana Claudia Latronico, Berenice B Mendonca, Jose L Chambô and 1 more

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eduardo PatoDivision of Urology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.ORCID https://orcid.org/0000-0003-2747-8402
Victor SrougiDivision of Urology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.ORCID https://orcid.org/0000-0001-8346-3833
Claudia ZerbiniDivision of Pathology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Felipe L LedesmaDivision of Pathology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Fabio TannoDivision of Urology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Madson Q AlmeidaDivision of Endocrinology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
William NahasDivision of Urology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Ana Claudia LatronicoDivision of Endocrinology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Berenice B MendoncaDivision of Endocrinology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Jose L ChambôDivision of Urology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.
Maria Candida B V FragosoDivision of Endocrinology, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, SP 05403-010, Brazil.ORCID https://orcid.org/0000-0001-6150-1915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare and lethal disease with a poor prognosis. This study aims to share our 41-year experience as a referral center, focusing on identifying risk factors associated with ACC mortality. Our retrospective analysis included a cohort of 150 adult patients with ACC in all stage categories, treated between 1981 and 2022. Tumor hormonal hypersecretion was observed in 78.6% of the patients, and the median age of diagnosis was 40 years. The majority presented as European Network for the Study of Adrenal Tumors (ENSAT) III or IV (22.9% and 31.2%, respectively), and the overall mortality rate was 54.6%. Independent predictors of death were elevated secretion of cortisol (HR = 2.0), androstenedione (HR = 2.2), estradiol (HR = 2.8), 17-OH progesterone (HR = 2.0), and 11-deoxycortisol (HR = 5.1), higher Weiss (HR = 4.3), modified Weiss (HR = 4.4), and Helsinki scores (HR = 12.0), advanced ENSAT stage (HR = 27.1), larger tumor size (HR = 2.7), higher Ki-67 percentage (HR = 2.3), and incomplete surgical resection (HR = 2.5). Mitosis greater than 5/50 high-power field (HR = 5.6), atypical mitosis (HR = 2.3), confluent necrosis (HR = 15.4), venous invasion (HR = 2.8), and capsular invasion (HR = 2.4) were also identified as independent predictors of death. Knowing the risk factors for ACC's mortality may help determine the best treatment option.

Indexed as

adrenocortical carcinomahormonal hypersecretionmortalityrisk factors

Identifiers

PMID38384443
PMCPMC10881101

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.